Patent · US Active

Bispecific T cell activating antigen binding molecules

US10611841B2 · kind B2 · utility

4Cited by

28References

41Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Oliver Ast · Bassersdorf, CH
Marina BACAC · Schlieren, CH
Sabine Imhof-Jung · Planegg, DE
Christiane Neumann · Niederweningen, CH
Christian Klein · Iffeldorf, DE
Stefan Klostermann · Schwanau, DE
Michael Molhoj · Munich, DE
Joerg Thomas Regula · Munich, DE
Wolfgang Schaefer · Sankt Augustin, DE
Pablo Umana · Wollerau, CH

Key dates

Filing date	Jan 24, 2018
Grant date	Apr 7, 2020
Priority date	—
Expiry date	Jan 24, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.